Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4328 Health-related quality of life (HRQL) and supportive care needs (SCN) of gastroenteropancreatic neuroendocrine tumours (GEP-NET) in a Swiss NET Centre

Introduction: Health-related quality of life (HRQL) and supportive care needs (SCN) of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) remain understudied. Assessing and identifying the affected domains of HRQL and SCN of the patients with GEP-NET is part of the nursing practice and may contribute to adapt the nursing care.

Conference:

Presenting Author: Ho J

Authors: Ho J, Abdulle A, Messerli O, Eicher M, Schaefer N,

Keywords: gastroenteropancreatic neuroendocrine tumour, health related quality of life, quality of life, supportive care needs, unmet needs,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,

#3788 Patient initiated follow-up for surgically resected neuroendocrine tumor patients using a digital system – My Medical Record

Introduction: Patient Initiated Follow Up (PIFU) is well established in this regional cancer centre, it allows patients to contact a cancer specialist team based on symptoms and individual circumstances. Patients are empowered to manage follow-up remotely, undertaking cancer surveillance tests and accessing results through the digital system MyMedicalRecord (MyMR).

Conference:

Presenting Author:

Authors: Ramsey E, Marsh C, Jarvis E, Armstrong T, Knight J,

Keywords: surveillance, Patient-initiated follow-up, neuroendocrine tumor, follow-up,

#3579 Setting up of a national liver transplant programme for neuroendocrine tumor liver metastases in UK and Ireland: Opportunities for collaborations in clinical study and research

Introduction: Liver transplantation [LT] for unresectable neuroendocrine tumor liver metastases [NET LM] is one of three new cancer indications in UK and Ireland. Transplant benefit is only proven using the Milan criteria so patient selection needs to be meticulously objective. We have therefore created a national MDT to provide a formal framework, aid patient selection, oversee data collection, monitor performance, provide training and education, deliver equity of access, facilitate research and clinical trials.

Conference:

Presenting Author:

Authors: Shah T, Gibbs P, Moore J, Venkataraman H, O'Toole D,

Keywords: liver transplantation, neuroendocrine tumor liver metastasis, neuroendocrine tumor surgery,

#3517 The role of the NET clinical nurse specialist in managing carcinoid heart disease patients: Optimising patient care

Introduction: The diagnosis of carcinoid heart disease (CHD) is often made late and requires a highly experienced team to manage multiple issues, such as heart failure, carcinoid symptoms and poor nutrition. Prior to December 2018 NET (Neuroendocrine Tumor) and cardiac teams were working in isolation, this resulted in missed opportunities for intervention and comprehensive review. It was evident we needed to build closer collaborations with our cardiac colleagues, to ensure timely assessment, optimisation of symptoms and improve patients’ overall experience. The Clinical Nurse Specialists (CNSs) were fundamental in establishing a twice monthly CHD/NET multidisciplinary team meeting and monthly joint NET/CHD clinic. Patients were kept informed at each stage by the CNS, either during telephone consultation, ward visit or at clinic appointments.

Conference:

Presenting Author:

Authors: Smith S, Vickrage S, Kemp-Blake J, Coldham C, Shah T,

Keywords: Carcinoid Heart Disease, Multidisciplinary team, Clinical Nurse Specialist,